In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin
暂无分享,去创建一个
D. Schmatz | J. Balkovec | K. Bartizal | G. Abruzzo | M. Hammond | F. Vanmiddlesworth | R. Schwartz | K. Nollstadt | D. Krupa | C. Trainor
[1] D. Stevens,et al. Synergy between cilofungin and amphotericin B in a murine model of candidiasis , 1991, Antimicrobial Agents and Chemotherapy.
[2] D. Schmatz,et al. L-687,781, a new member of the papulacandin family of beta-1,3-D-glucan synthesis inhibitors. I. Fermentation, isolation, and biological activity. , 1991, The Journal of antibiotics.
[3] M. Prevost,et al. Activity of cilofungin (LY 121019), a new lipopeptide antibiotic, on the cell wall and cytoplasmic membrane of Candida albicans. Structural modifications in scanning and transmission electron microscopy. , 1990, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[4] D. Schmatz,et al. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[5] R. Hector,et al. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis , 1990, Antimicrobial Agents and Chemotherapy.
[6] H. Gallis. Amphotericin B: 30 years of experience , 1990 .
[7] R. Fromtling,et al. L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin. , 1989, The Journal of antibiotics.
[8] R. Schwartz,et al. L-671,329, a new antifungal agent. I. Fermentation and isolation. , 1989, The Journal of antibiotics.
[9] R. Schwartz,et al. L-671,329, a new antifungal agent. II. Structure determination. , 1989, The Journal of antibiotics.
[10] A. Cassone,et al. Cell wall of Candida albicans: its functions and its impact on the host. , 1989, Current topics in medical mycology.
[11] T. Tegoshi,et al. Yeast glucan in the cyst wall of Pneumocystis carinii. , 1989, The Journal of protozoology.
[12] J. Ruiz-Herrera,et al. Fungal cell wall synthesis and assembly. , 1989, Current topics in medical mycology.
[13] R. Molloy,et al. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. , 1989, Annals of the New York Academy of Sciences.
[14] C. Selitrennikoff,et al. Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity , 1988, Antimicrobial Agents and Chemotherapy.
[15] W. Alborn,et al. Anti‐Candida Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal Antibiotic a , 1988, Annals of the New York Academy of Sciences.
[16] R. Wenzel,et al. Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. , 1988, Diagnostic microbiology and infectious disease.
[17] J. Galgiani. Antifungal susceptibility tests , 1987, Antimicrobial Agents and Chemotherapy.
[18] J. Galgiani,et al. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods , 1987, Antimicrobial Agents and Chemotherapy.
[19] P. Traxler,et al. Papulacandins--synthesis and biological activity of papulacandin B derivatives. , 1987, The Journal of antibiotics.
[20] M. Shepherd. Cell envelope of Candida albicans. , 1987, Critical reviews in microbiology.
[21] R. Sentandreu,et al. Tunicamycin and papulacandin B inhibit incorporation of specific mannoproteins into the wall of Candida albicans regenerating protoplasts. , 1986, Biochimica et biophysica acta.
[22] A. Thomas. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. , 1986, The Journal of antimicrobial chemotherapy.
[23] M. Osumi,et al. Effect of Aculeacin A, a Wall‐Active Antibiotic, on Synthesis of the Yeast Cell Wall , 1985, Microbiology and immunology.
[24] J W Tukey,et al. Testing the statistical certainty of a response to increasing doses of a drug. , 1985, Biometrics.
[25] P. Gopal,et al. Analysis of wall glucans from yeast, hyphal and germ-tube forming cells of Candida albicans. , 1984, Journal of general microbiology.
[26] D. Kerridge,et al. Echinocandin inhibition of 1,3‐β‐D‐glucan synthase from Candida albicans , 1984 .
[27] L. J. Nisbet,et al. The effect of aculeacin A and papulacandin B on morphology and cell wall ultrastructure in Candida albicans. , 1984, Canadian journal of microbiology.
[28] D. Berg,et al. Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. , 1984, Arzneimittel-Forschung.
[29] E. Cabib,et al. Synthesis of the yeast cell wall and its regulation. , 1982, Annual review of biochemistry.
[30] Pilar Pe´rez,et al. Effect of papulacandin B and aculeacin A on β‐(1,3) glucan‐synthase from geotrichum lactis , 1981 .
[31] D. Kerridge,et al. Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. , 1981, Sabouraudia.
[32] M S Marriott,et al. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. , 1980, Journal of general microbiology.
[33] B. Baguley,et al. Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts. , 1979, European journal of biochemistry.
[34] Biosynthesis of the Yeast Cell Wall I. PREPARATION AND PROPERTIES OF B-(l-+ 3)GLUCAN SYNTHETASE* , 2022 .